Avalo Therapeutics Inc. (AVTX)
NASDAQ · Healthcare
Avalo Therapeutics Inc. Shareholder Equity 2015–2025
Avalo Therapeutics Inc. annual shareholder equity history from 2015 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Avalo Therapeutics Inc. shareholder equity as of December 31, 2025: 83.0M, a 37.57% decrease year-over-year.
- Avalo Therapeutics Inc. shareholder equity for 2025 were 83.0M, a 37.57% decrease from 2024.
- Avalo Therapeutics Inc. shareholder equity for 2024 were 133.0M, a 1721.36% increase from 2023.
- Avalo Therapeutics Inc. shareholder equity for 2023 were 7.3M, a 166.92% decrease from 2022.
- Avalo Therapeutics Inc. shareholder equity for 2022 were -10.9M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Avalo Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $83 |
| 2024 | $133 |
| 2023 | $7 |
| 2022 | $-11 |
| 2021 | $23 |
| 2020 | $25 |
| 2019 | $21 |
| 2018 | $21 |
| 2017 | $28 |
| 2016 | $0 |
| 2015 | $13 |
Avalo Therapeutics Inc. Shareholder Equity — FAQ
Avalo Therapeutics Inc. (AVTX) shareholder equity over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see AVTX's shareholder equity history?
The chart and table above show Avalo Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.